Advanced therapy forum introduces engineering and gene therapy and regulations to keep up with science.
Speech by Lu Guanda, Senior Treatment Forum
The "Advanced Treatment Forum" was explained by Lu Guanda, an associate professor at MIT, with his expertise spanning medicine and engineering. Lu Guanda first introduced the application status of imported engineering in cell and gene therapy in recent years and the current product line of the new startup Senti. Lu Guanda shared the team's rich academic research experience. Through the field circuit technology that the team is good at, we can distinguish normal cells from tumor cells, successfully regulate the immune system, inhibit tumors, and can be used for the treatment of inflammatory diseases, metabolic diseases, hereditary diseases and cancer.
Wang Huamao, co-founder of Keji Bio * * * from Shanghai, shared the development and future of CAR-T cells in solid tumor treatment, and introduced the company's current product line for myeloma, gastric cancer, pancreatic cancer and leukemia. In addition, Hiroyuki Shimasaka, chairman of the Asian Cell Therapy Organization, is also one of the speakers of today's "Advanced Therapy". He shared the current situation of cell therapy industry in Japan and the world with multinational and years of legal experience. It is emphasized that team communication and education are the key to keep laws and regulations in step with scientific development, and many topics such as how to define "therapy and products", relevant norms of storage, transportation and manufacturing of international organizations, and how laws and regulations can promote the development of advanced therapies on the premise of protecting patients' safety are discussed.
Cross-Strait Biomedical Forum opens cross-strait cooperation and creates a win-win situation for both sides.
Participants discuss cross-strait biomedical business opportunities
Another "Cross-Strait Biomedical Forum" focused on cross-strait cooperation in biotechnology and pharmaceutical industry in China, talking about how to open cross-strait cooperation and find trustworthy partners. Among them, Ye Changqing, general manager of Zhiqing Biotechnology, said in his speech: China has great determination to promote medical and health undertakings in recent years, including consistency evaluation reform, self-verification of drug clinical trial data, Sino-US double reporting, and joining ICH, etc. It is hoped that the two sides will carry out more biomedical cooperation in the future, with the goal of going global.
Zhang Mingkui, CEO of Xinxu Biotechnology, shared the current situation of the company's layout in Taiwan Province Province and Japan, showing his determination to enter the China market. Zhang Mingkui pointed out that the innovative imaging technology jointly developed by Xinxu and the National Institute of Radiomedicine (QST) can analyze protein in the brain of Alzheimer's disease, and antibodies and small molecules are being developed to treat protein deposited in the brain of Alzheimer's disease. The developed image tracker is the only one with the best imaging performance at present. At present, there are four countries: Taipei, Suzhou, Japan and the United States. I hope to conduct clinical trials in China in the future, and carry out cross-strait cooperation, drug research and development and technical exchanges.
Chen, general manager of Jianya Biotechnology, shared the successful cases of cross-strait strategic cooperation and more than a dozen successful experiences of reinvestment in recent years, and listed the advantages and disadvantages between the two sides of the strait, as well as specific cooperation suggestions. Only by knowing ourselves and ourselves can we have a better chance to create a win-win situation for both sides of the strait.
"Business Opportunities in Southeast Asia" Drug dealers in Taiwan Province Province intend to enter Southeast Asian countries to maintain good relations.
Group photo of some people attending BBA meeting.
Kang Zhaozhou, Dean of the School of Pharmacy of Yangming University, pointed out in his speech that Taiwan Province's southward policy began as early as 20 years ago, and successive presidents also took a fancy to the business opportunities in the south. This time, Cai * * * actively promoted the new southward policy, and the key breakthrough in the Asian regional strategy was echoed by Southeast Asian and South Asian countries.
Sarissa Chancatch, general manager of SYMGENS Company * * * I pointed out that the FDA of Thailand has updated relevant laws and policies, shortening the period from clinical trial, registration and inspection, approval and licensing to listing from the past 18-24 months to 6- 12 months. She suggested that foreign-funded enterprises interested in entering the Thai market should seek local professional partners for cooperation and consult local officials or industries with decision-making power? Keep a good relationship.
Thomas Luke, president of the Philippine Pharmaceutical Association, also said that there are no real biological drugs and similar drugs in the Philippines, and the original patented drugs and generic drugs are still the main ones, with the original patented drugs accounting for the bulk, while the generic drugs come from Pakistan, India, China and so on. Thomas Luke reminded that at present, there are no laws and regulations on biologically similar drugs in the Philippines, but they are evaluated by vaccines and drugs as an advantage to enter the Philippine market.
The three-day BBA forum was heated and received enthusiastic response, especially under the exchange of transnational summit forums, which gave Taiwan Province and private enterprises the opportunity to integrate with the international community in recent years, and was also conducive to long-term industrial development.